$3.20
+0.12 (+3.90%)
Open$3.23
Previous Close$3.08
Day High$3.54
Day Low$3.05
52W High$3.45
52W Low$0.29
Volume—
Avg Volume388.7K
Market Cap186.52M
P/E Ratio—
EPS$-0.32
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+742.5% upside
Current
$3.20
$3.20
Target
$26.96
$26.96
$18.17
$26.96 avg
$35.46
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 68.45M | 35.55M | 33.75M |
| Net Income | -13,439,175 | 3.58M | 3.41M |
| Profit Margin | -19.6% | 10.1% | 10.1% |
| EBITDA | -14,905,588 | 5.92M | 5.34M |
| Free Cash Flow | — | 3.84M | 3.54M |
| Rev Growth | — | -9.4% | +19.8% |
| Debt/Equity | — | 0.12 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |